A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
LIMMITLESS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
3 other identifiers
interventional
2,170
16 countries
226
Brief Summary
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2017
Longer than P75 for phase_3
226 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 7, 2017
CompletedFirst Posted
Study publicly available on registry
February 9, 2017
CompletedStudy Start
First participant enrolled
February 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 29, 2023
CompletedResults Posted
Study results publicly available
December 11, 2024
CompletedDecember 11, 2024
November 1, 2024
6.8 years
February 7, 2017
November 19, 2024
November 19, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants With Serious Adverse Events and Non-Serious Adverse Events
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Median follow-up time of 1905 days
Study Arms (1)
Risankizumab
EXPERIMENTALParticipants will receive risankizumab administered by subcutaneous injection.
Interventions
Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
Eligibility Criteria
You may qualify if:
- Participants with a history of moderate to severe chronic plaque psoriasis, who have completed one of the preceding studies.
- Participants must be candidates for prolonged open label risankizumab treatment according to investigator judgment.
- Females of childbearing potential must have a negative urine pregnancy test result at Baseline.
- If female, participant must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential practicing at least one protocol specified method of birth control, starting at Baseline through at least 20 weeks after the last dose of study drug.
- \- Participants must have signed and dated a written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission into the study.
You may not qualify if:
- Premature discontinuation for any reason in the preceding study.
- Participants who have developed guttate, erythrodermic, pustular or drug-induced psoriasis as diagnosed by the investigator during the preceding study.
- Use of any prohibited medication or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator.
- Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse) other than psoriasis, surgical procedure (i.e., organ transplant), medical examination finding (including vital signs and ECG), or laboratory value outside the reference range that in the opinion of the investigator is clinically significant and would make the study participant unreliable to adhere to the protocol or to complete the study, compromise the safety of the subject, or compromise the quality of the data.
- Previous enrollment in this study.
- Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or within 20 weeks after the last dose of study drug.
- Time elapsed is \> 8 weeks since the completion visit in the preceding study.
- Participant is considered by the investigator for any reason, to be an unsuitable candidate for the study and not able to comply with the study protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (233)
Total Skin and Beauty Dermatology Center /ID# 154000
Birmingham, Alabama, 35205, United States
University of Alabama at Birmingham - Main /ID# 153983
Birmingham, Alabama, 35233, United States
NW Arkansas Clinical Trials Center /ID# 154014
Rogers, Arkansas, 72758, United States
Bakersfield Derma & Skin Cance /ID# 154008
Bakersfield, California, 93309, United States
California Dermatology and Research Institute /ID# 154007
Encinitas, California, 92024, United States
T. Joseph Raoof, MD, Inc. /ID# 154078
Encino, California, 91436, United States
Center for Dermatology Clinical Research /ID# 154009
Fremont, California, 94538, United States
Kaiser Permanente Los Angeles /ID# 154079
Los Angeles, California, 90027, United States
Dermatology Research Associates /ID# 153977
Los Angeles, California, 90045, United States
Wallace Medical Group /ID# 154025
Los Angeles, California, 90056, United States
Dermatology Specialists, Inc /ID# 153984
Oceanside, California, 92056, United States
Huntington Medical Foundation /ID# 154002
Pasadena, California, 91105, United States
Medderm Associates /ID# 154098
San Diego, California, 92103, United States
Southern California Dermatology /ID# 154006
Santa Ana, California, 92701, United States
UNISON Center for Clinical Tri /ID# 153979
Sherman Oaks, California, 91403, United States
New England Research Associates, LLC /ID# 154004
Bridgeport, Connecticut, 06606-1827, United States
UConn Health /ID# 154128
Farmington, Connecticut, 06030, United States
Florida Academic Centers Research /ID# 154045
Coral Gables, Florida, 33134, United States
Leavitt Medical Associates of Florida /ID# 154046
Ormond Beach, Florida, 32174, United States
Progressive Medical Research /ID# 154027
Port Orange, Florida, 32127, United States
Hamilton Research, LLC /ID# 153980
Alpharetta, Georgia, 30022, United States
Advanced Medical Research, PC /ID# 153999
Sandy Springs, Georgia, 30328-6141, United States
Northwestern University Feinberg School of Medicine /ID# 153974
Chicago, Illinois, 60611-2927, United States
Rush University Medical Center /ID# 154099
Chicago, Illinois, 60612, United States
Arlington Dermatology /ID# 153975
Rolling Meadows, Illinois, 60008, United States
Northshore University Health System Dermatology Clinical Trials Unit /ID# 154011
Skokie, Illinois, 60077, United States
Dundee Dermatology /ID# 154110
West Dundee, Illinois, 60118, United States
Dawes Fretzin, LLC /ID# 154146
Indianapolis, Indiana, 46256, United States
The Dermatology Center PSC - New Albany /ID# 154075
New Albany, Indiana, 47150, United States
The Indiana Clinical Trials Center /ID# 153976
Plainfield, Indiana, 46168, United States
The South Bend Clinic Center /ID# 154147
South Bend, Indiana, 46617, United States
Epiphany Dermatology of Kansas LLC /ID# 153993
Overland Park, Kansas, 66210, United States
Skin Sciences, PLLC /ID# 153991
Louisville, Kentucky, 40217, United States
DS Research /ID# 154028
Louisville, Kentucky, 40241, United States
Massachusetts General Hospital /ID# 153990
Boston, Massachusetts, 02114, United States
ActivMed Practices and Research, LLC. /ID# 154044
Methuen, Massachusetts, 01844, United States
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 154111
Ann Arbor, Michigan, 48109, United States
Great Lakes Research Group - Bay City /ID# 153998
Bay City, Michigan, 48706, United States
Michigan Center for Skin Care Research /ID# 153986
Clinton Township, Michigan, 48038, United States
Somerset Skin Centre /ID# 154097
Troy, Michigan, 48084, United States
Minnesota Clinical Study Center /ID# 154015
New Brighton, Minnesota, 55112, United States
Central Dermatology, PC /ID# 154013
St Louis, Missouri, 63117, United States
Skin Specialists, PC /ID# 154024
Omaha, Nebraska, 68144, United States
Dartmouth-Hitchcock Medical Center /ID# 154095
Lebanon, New Hampshire, 03756, United States
Psoriasis Treatment Center of Central New Jersey /ID# 154001
East Windsor, New Jersey, 08520, United States
Schweiger Dermatology Group /ID# 202489
Verona, New Jersey, 07044, United States
Forest Hills Dermatology Group /ID# 154113
Kew Gardens, New York, 11415, United States
Icahn School of Medicine at Mount Sinai /ID# 154129
New York, New York, 10029, United States
The Rockefeller University /ID# 153994
New York, New York, 10065, United States
DermResearchCenter of New York, Inc. /ID# 154012
Stony Brook, New York, 11790, United States
Buffalo Medical Group /ID# 154148
Williamsville, New York, 14221, United States
Darst Dermatology /ID# 154076
Charlotte, North Carolina, 28277, United States
Dermatology Consulting Service /ID# 154010
High Point, North Carolina, 27262, United States
Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 202490
Raleigh, North Carolina, 27612, United States
Wilmington Dermatology Center /ID# 154109
Wilmington, North Carolina, 28403, United States
Synexus Research Cincinnati /ID# 153997
Cincinnati, Ohio, 45236, United States
Oregon Dermatology and Research Center /ID# 153982
Portland, Oregon, 97210, United States
Oregon Medical Research Center /ID# 154003
Portland, Oregon, 97223, United States
Altoona Ctr Clinical Res /ID# 153981
Duncansville, Pennsylvania, 16635, United States
Paddington Testing Co., Inc. /ID# 154022
Philadelphia, Pennsylvania, 19103, United States
University of Pittsburgh MC /ID# 153995
Pittsburgh, Pennsylvania, 15260, United States
Clinical Partners, LLC /ID# 154096
Johnston, Rhode Island, 02919, United States
Coastal Clinical Research Center of the Carolinas /ID# 154112
Charleston, South Carolina, 29414, United States
Synexus Clinical Research US, Inc. /ID# 154127
Greer, South Carolina, 29651-1123, United States
Coastal Carolina Research Center /ID# 153992
North Charleston, South Carolina, 29405, United States
Health Concepts /ID# 153996
Rapid City, South Dakota, 57702, United States
Austin Dermatology Associates /ID# 154042
Austin, Texas, 78705, United States
Bellaire Dermatology Associates /ID# 153987
Bellaire, Texas, 77401, United States
Modern Research Associates, PLLC /ID# 154043
Dallas, Texas, 75231, United States
Menter Dermatology Res Inst /ID# 153985
Dallas, Texas, 75246, United States
Center for Clinical Studies - Houston (Binz) /ID# 154005
Houston, Texas, 77004-8097, United States
Suzanne Bruce and Associates-Houston /ID# 154026
Houston, Texas, 77056, United States
Derm Clin Res Ctr San Antonio /ID# 153978
San Antonio, Texas, 78229, United States
Progressive Clinical Research /ID# 154149
San Antonio, Texas, 78229, United States
Dermatology San Antonio /ID# 154077
San Antonio, Texas, 78249, United States
Center for Clinical Studies Webster TX /ID# 154150
Webster, Texas, 77598, United States
Virginia Clinical Research, Inc. /ID# 154016
Norfolk, Virginia, 23502, United States
Dermatology Associates of Seattle /ID# 153988
Seattle, Washington, 98101, United States
Premier Clinical Research /ID# 154284
Spokane, Washington, 99202, United States
Paratus Clinical Research Woden /ID# 154307
Phillip, Australian Capital Territory, 2606, Australia
St George Dermatology & Skin Cancer Centre /ID# 154308
Kogarah, New South Wales, 2217, Australia
Specialist Connect Pty Ltd /ID# 154311
Woolloongabba, Queensland, 4102, Australia
North Eastern Health Specialists /ID# 154309
Campbelltown, South Australia, 5074, Australia
Skin Health Institute Inc /ID# 154305
Carlton, Victoria, 3053, Australia
Sinclair Dermatology - Melbourne /ID# 154310
Melbourne, Victoria, 3995, Australia
Fremantle Dermatology /ID# 154306
Fremantle, Western Australia, 6160, Australia
Klinik Landstrasse /ID# 154300
Vienna, Vienna, 1030, Austria
Medizinische Universitaet Wien /ID# 154302
Vienna, Vienna, 1090, Austria
Landeskrankenhaus Feldkirch /ID# 154303
Feldkirch, Vorarlberg, 6800, Austria
Cliniques Universitaires de Bruxelles Hopital Erasme /ID# 154293
Brussels, Brussels Capital, 1070, Belgium
Universitair Ziekenhuis Brussel /ID# 154295
Jette, Brussels Capital, 1090, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 154294
Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium
CHU de Liege Sart Tilman /ID# 154297
Liège, Liege, 4000, Belgium
UZ Gent /ID# 154296
Ghent, Oost-Vlaanderen, 9000, Belgium
IMTR - Grand Hopital de Charleroi /ID# 154298
Loverval, 6280, Belgium
Kirk Barber Research, CA /ID# 153840
Calgary, Alberta, T2G 1B1, Canada
Dermatology Research Institute Inc. /ID# 153850
Calgary, Alberta, T2J 7E1, Canada
Stratica Medical /ID# 153848
Edmonton, Alberta, T5K 1X3, Canada
Dr. Chih-ho Hong Medical Inc. /ID# 153842
Surrey, British Columbia, V3R 6A7, Canada
Enverus Medical Research /ID# 153851
Surrey, British Columbia, V3V 0C6, Canada
Karma Clinical Trials /ID# 153876
St. John's, Newfoundland and Labrador, A1A 4Y3, Canada
Eastern Canada Cutaneous Resea /ID# 153870
Halifax, Nova Scotia, B3H 1Z2, Canada
CCA Medical Research /ID# 153859
Ajax, Ontario, L1S 7K8, Canada
Kingsway Clinical Research /ID# 154292
Etobicoke, Ontario, M8X 1Y9, Canada
Dermatrials Research /ID# 153847
Hamilton, Ontario, L8N 1Y2, Canada
The Guenther Dermatology Research Centre /ID# 153841
London, Ontario, N6A 3H7, Canada
Lynderm Research Inc. /ID# 153861
Markham, Ontario, L3P 1X3, Canada
DermEdge Research Inc. /ID# 153843
Mississauga, Ontario, L4Y 4C5, Canada
North Bay Dermatology Centre /ID# 153845
North Bay, Ontario, P1B 3Z7, Canada
The Centre for Clinical Trials /ID# 153871
Oakville, Ontario, L6J 7W5, Canada
Dermatology Ottawa Research Centre /ID# 153862
Ottawa, Ontario, K2C 3N2, Canada
SKiN Centre for Dermatology /ID# 153853
Peterborough, Ontario, K9J 5K2, Canada
The Center For Dermatology /ID# 153844
Richmond Hill, Ontario, L4B 1A5, Canada
York Dermatology Clinic and Research Centre /ID# 153860
Richmond Hill, Ontario, L4C 9M7, Canada
Toronto Research Centre /ID# 153852
Toronto, Ontario, M3H 5Y8, Canada
Research Toronto /ID# 153854
Toronto, Ontario, M4W 2N4, Canada
K. Papp Clinical Research /ID# 153855
Waterloo, Ontario, N2J 1C4, Canada
XLR8 Medical Research /ID# 153858
Windsor, Ontario, N8W 1E6, Canada
Windsor Clinical Research, Inc /ID# 153877
Windsor, Ontario, N8W 5L7, Canada
Innovaderm Research Inc. /ID# 153846
Montreal, Quebec, H2X 2V1, Canada
Centre de Recherche dermatologique du Quebec Metropolitain /ID# 153856
Québec, Quebec, G1V 4X7, Canada
DERMAMEDICA, s.r.o. /ID# 153890
Červený Kostelec, 549 41, Czechia
Medical research s.r.o. /ID# 153898
Ostrava, 735 14, Czechia
Clintrial s.r.o. /ID# 153889
Prague, 100 00, Czechia
MUDr. Blanka Havlickova - dermatovenerologie /ID# 153888
Prague, 110 00, Czechia
Pratia Prague s.r.o. /ID# 153897
Prague, 130 00, Czechia
CCR Czech a.s /ID# 153887
Prague, 140 00, Czechia
Terveystalo Tampere /ID# 154118
Tampere, 33100, Finland
Mehilainen Turku /ID# 154120
Turku, 20100, Finland
Chu de Nice-Hopital Larchet Ii /Id# 153948
Nice, Alpes-Maritimes, 06200, France
Hôpital Charles-Nicolle /ID# 205842
Rouen, 76000, France
CHU Toulouse - Hopital Larrey /ID# 153951
Toulouse, 31400, France
Universitaetsklinik Heidelberg /ID# 153910
Heidelberg, Baden-Wurttemberg, 69120, Germany
Universitaetsklinikum Tuebingen /ID# 153912
Tübingen, Baden-Wurttemberg, 72076, Germany
Universitaetsklinikum Erlangen /ID# 154093
Erlangen, Bavaria, 91054, Germany
Dermatologische Gemeinschaftspraxis Mahlow /ID# 153892
Blankenfelde-Mahlow, Brandenburg, 15831, Germany
Klinikum Darmstadt GmbH /ID# 153893
Darmstadt, Hesse, 64283, Germany
Universitaetsklinikum Frankfurt /ID# 153891
Frankfurt am Main, Hesse, 60590, Germany
Universitaetsklinikum Muenster /ID# 153895
Munster, Lower Saxony, 48149, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 154092
Mainz, Rhineland-Palatinate, 55131, Germany
CMS3 Company for Medical Study /ID# 201318
Selters, Rhineland-Palatinate, 56242, Germany
Universitaetsklinikum Leipzig /ID# 153909
Leipzig, Saxony, 04103, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 153916
Kiel, Schleswig-Holstein, 24105, Germany
DermaKiel Allergie und Haut Centrum /ID# 201316
Kiel, Schleswig-Holstein, 24148, Germany
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 153896
Berlin, 10117, Germany
ISA Interdisciplinary Study Association GmbH /ID# 153907
Berlin, 10789, Germany
Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus /ID# 154289
Bochum, 44793, Germany
Universitaetsklinikum Bonn /ID# 154094
Bonn, 53127, Germany
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 153906
Dresden, 01307, Germany
Universitaetsmedizin Goettingen /ID# 154091
Göttingen, 37075, Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 154089
Hamburg, 20246, Germany
Klinische Forschung Hamburg GmbH /ID# 154290
Hamburg, 20253, Germany
TFS Trial Form Support GmbH /ID# 153894
Hamburg, 20537, Germany
Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 153915
Munich, 81675, Germany
Klinische Forschung Schwerin GmbH /ID# 154291
Schwerin, 19055, Germany
Hautarztpraxis Dr. med. Matthias Hoffmann /ID# 153917
Witten, 58453, Germany
CentroDerm GmbH /ID# 153914
Wuppertal, 42287, Germany
Nagoya City University Hospital /ID# 153866
Nagoya, Aichi-ken, 467-8602, Japan
Fukuoka University Hospital /ID# 153864
Fukuoka, Fukuoka, 814-0180, Japan
Kurume University Hospital /ID# 156320
Kurume-shi, Fukuoka, 830-0011, Japan
Fukushima Medical University Hospital /ID# 153873
Fukushima, Fukushima, 960-1295, Japan
Gifu University Hospital /ID# 169410
Gifu, Gifu, 501-1194, Japan
JR Sapporo Hospital /ID# 201963
Sapporo, Hokkaido, 060-0033, Japan
Medical Corporation Kojinkai Sapporo Skin Clinic /ID# 154083
Sapporo, Hokkaido, 060-0063, Japan
Hokkaido University Hospital /ID# 154285
Sapporo, Hokkaido, 060-8648, Japan
Kobe University Hospital /ID# 170706
Kobe, Hyōgo, 650-0017, Japan
Iwate Medical University Hospital /ID# 170843
Shiwa-gun, Iwate, 028-3695, Japan
Kagawa University Hospital /ID# 168656
Kita-gun, Kagawa-ken, 761-0793, Japan
Japan Organization of Occupational Health and Society Kanto Rosai Hospital /ID# 169172
Kawasaki-shi, Kanagawa, 211-8510, Japan
National Hospital Organization Sagamihara National Hospital /ID# 153867
Sagamihara-shi, Kanagawa, 252-0392, Japan
Yokohama City University Hospital /ID# 168831
Yokohama, Kanagawa, 236-0004, Japan
University Hospital Kyoto Prefectural University of Medicine /ID# 169415
Kyoto, Kyoto, 602-8566, Japan
Kyoto University Hospital /ID# 156318
Kyoto, Kyoto, 606-8507, Japan
Mie University Hospital /ID# 156317
Tsu, Mie-ken, 514-8507, Japan
Tohoku University Hospital /ID# 169006
Sendai, Miyagi, 9808574, Japan
Shinshu University Hospital /ID# 170937
Matsumoto-shi, Nagano, 390-8621, Japan
Nagasaki University Hospital /ID# 170219
Nagasaki, Nagasaki, 852-8501, Japan
Okayama University Hospital /ID# 200631
Okayama, Okayama-ken, 700-8558, Japan
Kansai Medical University Hospital /ID# 170884
Hirakata-shi, Osaka, 573-1191, Japan
Osaka Metropolitan University Hospital /ID# 153869
Osaka, Osaka, 545-8586, Japan
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 156319
Osaka, Osaka, 550-0006, Japan
Kindai University Hospital /ID# 153865
Osakasayama-shi, Osaka, 589-8511, Japan
Osaka University Hospital /ID# 156321
Suita-shi, Osaka, 565-0871, Japan
Hamamatsu University Hospital /ID# 170132
Hamamatsu, Shizuoka, 431-3192, Japan
Jichi Medical University Hospital /ID# 154286
Shimotsuke-shi, Tochigi, 329-0498, Japan
Juntendo University Hospital /ID# 200292
Bunkyo-ku, Tokyo, 113-8431, Japan
Nippon Medical School Hospital /ID# 154084
Bunkyo-ku, Tokyo, 113-8602, Japan
Tokyo Teishin Hospital /ID# 165912
Chiyoda-ku, Tokyo, 102-8798, Japan
St.Luke's International Hospital /ID# 153863
Chuo-ku, Tokyo, 104-8560, Japan
Teikyo University Hospital /ID# 154287
Itabashi-ku, Tokyo, 173-8606, Japan
Nihon University Itabashi Hospital /ID# 154081
Itabashi-ku, Tokyo, 173-8610, Japan
The Jikei University Hospital /ID# 154080
Minato-ku, Tokyo, 105-8471, Japan
NTT Medical Center Tokyo /ID# 154082
Shinagawa-ku, Tokyo, 141-8625, Japan
Tokyo Medical University Hospital /ID# 153874
Shinjuku-ku, Tokyo, 160-0023, Japan
Japan Community Health care Organization Tokyo Yamate Medical Center /ID# 153868
Shinjuku-ku, Tokyo, 169-0073, Japan
Yamaguchi University Hospital /ID# 156322
Ube-shi, Yamaguchi, 755-8505, Japan
Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 153882
Monterrey, Nuevo León, 64460, Mexico
Derma Norte del Bajio S.C. /ID# 153880
Aguascalientes, 20130, Mexico
Centro de Dermatologia de Monterrey /ID# 153881
Monterrey, 64640, Mexico
Solumed Centrum Medyczne /ID# 153466
Poznan, Greater Poland Voivodeship, 60-529, Poland
Pratia MCM Krakow /ID# 153472
Krakow, Lesser Poland Voivodeship, 30-727, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocawiu /ID# 153473
Wroclaw, Lower Silesian Voivodeship, 50-556, Poland
KO-MED Centra Kliniczne Lublin /ID# 153469
Lublin, Lublin Voivodeship, 20-362, Poland
High-Med Przychodnia Specjalistyczna /ID# 153468
Warsaw, Masovian Voivodeship, 01-817, Poland
Klinika Ambroziak Sp. z o.o. /ID# 153467
Warsaw, Masovian Voivodeship, 02-953, Poland
Osteo-Medic S.C. /ID# 156535
Bialystok, Podlaskie Voivodeship, 15-351, Poland
Uniwersyteckie Centrum Kliniczne /ID# 153471
Gdansk, Pomeranian Voivodeship, 80-214, Poland
Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 153884
Gdansk, Pomeranian Voivodeship, 80-546, Poland
Dermoklinika Medical Center /ID# 153470
Lodz, Łódź Voivodeship, 90-436, Poland
2CA-Braga, Hospital de Braga /ID# 156323
Braga, 4710-243, Portugal
Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 153462
Lisbon, 1649-035, Portugal
CHP, EPE- Hospital Geral de Sa /ID# 153464
Porto, 4050, Portugal
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 153463
Porto, 4200-319, Portugal
Gachon University Gil Medical Center /ID# 153489
Incheon, Gyeonggido, 21565, South Korea
Seoul National University Bundang Hospital /ID# 153491
Seongnam, Gyeonggido, 13620, South Korea
Chonnam National University Hospital /ID# 153488
Gwangju, Jeonranamdo, 61469, South Korea
KonKuk University Medical Center /ID# 153483
Seoul, Seoul Teugbyeolsi, 05030, South Korea
Korea Universtiy Guro Hospital /ID# 153490
Seoul, Seoul Teugbyeolsi, 08308, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 153486
서초구, Seoul Teugbyeolsi, 06591, South Korea
Pusan National University Hospital /ID# 153485
Busan, 49241, South Korea
Seoul National University Hospital /ID# 153484
Seoul, 03080, South Korea
Samsung Medical Center /ID# 153487
Seoul, 06351, South Korea
Hospital Universitario Germans Trias i Pujol /ID# 153465
Badalona, Barcelona, 08916, Spain
Hospital Santa Creu i Sant Pau /ID# 154125
Barcelona, 08041, Spain
Hospital Universitario Infanta Leonor /ID# 154121
Madrid, 28031, Spain
Hospital General Universitario de Valencia /ID# 154126
Valencia, 46014, Spain
Karolinska University Hospital Solna /ID# 154131
Solna, Stockholm County, 171 64, Sweden
Sahlgrenska University Hospital /ID# 154132
Gothenburg, Västra Götaland County, 413 46, Sweden
Sodersjukhuset /ID# 154130
Stockholm, 118 83, Sweden
National Taiwan University Hospital /ID# 154136
Taipei City, Taipei, 100, Taiwan
Taipei Medical University Shuang Ho Hospital /ID# 154134
New Taipei City, 23561, Taiwan
National Cheng Kung University Hospital /ID# 154135
Tainan, 704, Taiwan
Taiwan Adventist Hospital /ID# 154137
Taipei, 105, Taiwan
Related Publications (4)
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Wu T, Rubant S, Bialik B, Ashley D, Soliman AM, Chen MM, Blauvelt A. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. Am J Clin Dermatol. 2025 Sep;26(5):829-841. doi: 10.1007/s40257-025-00964-6. Epub 2025 Jul 29.
PMID: 40728772DERIVEDAlexis AF, Gooderham M, Kwatra SG, Amin A, Taylor S, Espaillat R, Rettig T, Wu T, Shi L, Kaldas MI, Dilley DM, Sinvhal R, Nduaka C, Lockshin B. A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis. Dermatol Ther (Heidelb). 2024 Oct;14(10):2877-2887. doi: 10.1007/s13555-024-01268-z. Epub 2024 Oct 2.
PMID: 39358667DERIVEDHsieh CY, Hsu FL, Tsai TF. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2607-2620. doi: 10.1007/s13555-024-01229-6. Epub 2024 Jul 29.
PMID: 39073712DERIVEDPapp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021 Dec;185(6):1135-1145. doi: 10.1111/bjd.20595. Epub 2021 Sep 21.
PMID: 34157132DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Medical Services
- Organization
- AbbVie
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 7, 2017
First Posted
February 9, 2017
Study Start
February 27, 2017
Primary Completion
November 29, 2023
Study Completion
November 29, 2023
Last Updated
December 11, 2024
Results First Posted
December 11, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
- Time Frame
- For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
- Access Criteria
- Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.